Ando K - Search Results

1

The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury.

Hara R, Onizuka M, Shiraiwa S, Harada K, Aoyama Y, Ogiya D, Toyosaki M, Suzuki R, Machida S, Ohmachi K, Ogawa Y, Kawada H, Watanabe S, Miyajima A, Masuda R, Iwazaki M, Mikami M, Koike T, Mochizuki H, Ando K. Hara R, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e321-e327. doi: 10.1016/j.clml.2020.10.004. Epub 2020 Oct 9. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33127326

2

Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction.

Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, Fukuda K. Kawada H, et al. Blood. 2004 Dec 1;104(12):3581-7. doi: 10.1182/blood-2004-04-1488. Epub 2004 Aug 5. Blood. 2004. PMID: 15297308 Free article.

3

Potential and origin of the hematopoietic population in human skeletal muscle.

Tsuboi K, Kawada H, Toh E, Lee YH, Tsuma M, Nakamura Y, Sato T, Ando K, Mochida J, Kato S, Hotta T. Tsuboi K, et al. Leuk Res. 2005 Mar;29(3):317-24. doi: 10.1016/j.leukres.2004.08.005. Leuk Res. 2005. PMID: 15661268

4

Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.

Hayashida K, Fujita J, Miyake Y, Kawada H, Ando K, Ogawa S, Fukuda K. Hayashida K, et al. Chest. 2005 May;127(5):1793-8. doi: 10.1378/chest.127.5.1793. Chest. 2005. PMID: 15888860

5

Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells.

Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, Fukuda K, Takagi S, Okano H, Ando K, Hotta T. Kawada H, et al. Circulation. 2006 Feb 7;113(5):701-10. doi: 10.1161/CIRCULATIONAHA.105.563668. Circulation. 2006. PMID: 16461843

6

Health-related quality of life among Japanese women with iron-deficiency anemia.

Ando K, Morita S, Higashi T, Fukuhara S, Watanabe S, Park J, Kikuchi M, Kawano K, Wasada I, Hotta T. Ando K, et al. Qual Life Res. 2006 Dec;15(10):1559-63. doi: 10.1007/s11136-006-0030-z. Epub 2006 Jul 7. Qual Life Res. 2006. PMID: 16826432

7

Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia.

Suzuki R, Onizuka M, Kojima M, Shimada M, Fukagawa S, Tsuboi K, Kobayashi H, Shintani A, Ogawa Y, Kawada H, Hotta T, Ando K. Suzuki R, et al. Br J Haematol. 2007 Sep;138(5):624-31. doi: 10.1111/j.1365-2141.2007.06702.x. Br J Haematol. 2007. PMID: 17686056

8

Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease.

Shimada M, Onizuka M, Machida S, Suzuki R, Kojima M, Miyamura K, Kodera Y, Inoko H, Ando K. Shimada M, et al. Br J Haematol. 2007 Nov;139(3):458-63. doi: 10.1111/j.1365-2141.2007.06797.x. Epub 2007 Sep 14. Br J Haematol. 2007. PMID: 17868046

9

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.

Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, Taji H, Minami H, Itoh K, Nakata M, Hotta T. Ogawa Y, et al. Cancer Sci. 2008 Jan;99(1):140-4. doi: 10.1111/j.1349-7006.2007.00638.x. Epub 2007 Oct 27. Cancer Sci. 2008. PMID: 17970782 Free PMC article. Clinical Trial.

10

Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.

Suzuki R, Onizuka M, Kojima M, Shimada M, Okamura K, Fukagawa S, Tsuboi K, Kikuchi A, Kobayashi H, Shintani A, Ogawa Y, Kawada H, Hotta T, Ando K. Suzuki R, et al. Int J Hematol. 2007 Dec;86(5):422-8. doi: 10.1007/BF02984000. Int J Hematol. 2007. PMID: 18192111

11

[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].

Tsuboi K, Kawada H, Suzuki R, Murayama H, Ohmachi K, Nakamura N, Ogawa Y, Ando K. Tsuboi K, et al. Rinsho Ketsueki. 2008 Nov;49(11):1562-5. Rinsho Ketsueki. 2008. PMID: 19047789 Japanese.

12

Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.

Matsushita H, Masukawa A, Arakawa S, Ogawa Y, Asai S, Yabe M, Ando K, Miyachi H. Matsushita H, et al. Int J Hematol. 2009 Dec;90(5):623-626. doi: 10.1007/s12185-009-0448-5. Epub 2009 Dec 10. Int J Hematol. 2009. PMID: 19998064

13

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Cancer Sci. 2010 Sep;101(9):2054-8. doi: 10.1111/j.1349-7006.2010.01633.x. Cancer Sci. 2010. PMID: 20594195 Free PMC article. Clinical Trial.

14

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ohmachi K, et al. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x. Cancer Sci. 2010. PMID: 20626754 Free PMC article. Clinical Trial.

15

Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.

Kojima M, Sato E, Oshimi K, Murase T, Koike T, Tsunoda S, Matsumoto T, Marutsuka K, Ogiya D, Moriuchi M, Tokunaka M, Yara Kikuti Y, Kikuchi T, Nakamura N, Ando K. Kojima M, et al. J Clin Exp Hematop. 2010;50(2):107-12. doi: 10.3960/jslrt.50.107. J Clin Exp Hematop. 2010. PMID: 21123968 Free article.

16

Establishment of a xenograft model of human myelodysplastic syndromes.

Muguruma Y, Matsushita H, Yahata T, Yumino S, Tanaka Y, Miyachi H, Ogawa Y, Kawada H, Ito M, Ando K. Muguruma Y, et al. Haematologica. 2011 Apr;96(4):543-51. doi: 10.3324/haematol.2010.027557. Epub 2010 Dec 29. Haematologica. 2011. PMID: 21193418 Free PMC article.

17

Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.

Suzuki R, Onizuka M, Kojima M, Shimada M, Tsuboi K, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Tokai J Exp Clin Med. 2007 Dec 20;32(4):131-5. Tokai J Exp Clin Med. 2007. PMID: 21318952 Free article.

18

A case of essential thrombocythemia presenting with aortic thrombosis.

Oki M, Moriuchi M, Kawada H, Ogawa Y, Ando K. Oki M, et al. Tokai J Exp Clin Med. 2008 Dec 20;33(4):135-7. Tokai J Exp Clin Med. 2008. PMID: 21318983 Free article.

19

Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase.

Ohmachi K, Ogiya D, Morita F, Kojima M, Tsuboi K, Tazume K, Komatsu M, Hayama N, Kumaki N, Ogawa Y, Ando K. Ohmachi K, et al. Tokai J Exp Clin Med. 2008 Dec 20;33(4):146-9. Tokai J Exp Clin Med. 2008. PMID: 21318986 Free article.

20

A case of acquired aplastic anemia with repeated cerebral infarctions at the beginning of immunosuppressive therapy.

Suzuki R, Kikuchi A, Ohgiya D, Murayama H, Toyosaki M, Suyama T, Watanabe S, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Tokai J Exp Clin Med. 2009 Sep 20;34(3):58-62. Tokai J Exp Clin Med. 2009. PMID: 21319000 Free article.

21

Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.

Moriuchi M, Ohmachi K, Kojima M, Tsuboi K, Ogawa Y, Nakamura N, Ando K. Moriuchi M, et al. Tokai J Exp Clin Med. 2010 Apr 20;35(1):17-20. Tokai J Exp Clin Med. 2010. PMID: 21319020 Free article.

22

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Cancer Sci. 2011 Sep;102(9):1687-92. doi: 10.1111/j.1349-7006.2011.01994.x. Epub 2011 Jul 7. Cancer Sci. 2011. PMID: 21624007 Free article.

23

Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells.

Yahata T, Takanashi T, Muguruma Y, Ibrahim AA, Matsuzawa H, Uno T, Sheng Y, Onizuka M, Ito M, Kato S, Ando K. Yahata T, et al. Blood. 2011 Sep 15;118(11):2941-50. doi: 10.1182/blood-2011-01-330050. Epub 2011 Jul 6. Blood. 2011. PMID: 21734240 Free article.

24

Association of promyelocytic leukemia protein with expression of IL-6 and resistance to treatment in multiple myeloma.

Ohgiya D, Matsushita H, Onizuka M, Nakamura N, Amaki J, Aoyama Y, Kawai H, Ogawa Y, Kawada H, Ando K. Ohgiya D, et al. Acta Haematol. 2012;128(4):213-22. doi: 10.1159/000339486. Epub 2012 Aug 17. Acta Haematol. 2012. PMID: 22906876

25

Phase I study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke.

Moriya Y, Mizuma A, Uesugi T, Ohnuki Y, Nagata E, Takahashi W, Kobayashi H, Kawada H, Ando K, Takagi S, Takizawa S. Moriya Y, et al. J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1088-97. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.002. Epub 2012 Sep 6. J Stroke Cerebrovasc Dis. 2013. PMID: 22959110 Clinical Trial.

26

Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains.

Matsushita H, Nakamura N, Tanaka Y, Ohgiya D, Tanaka Y, Damdinsuren A, Asai S, Yabe M, Kawada H, Ogawa Y, Ando K, Miyachi H. Matsushita H, et al. Clin Chem Lab Med. 2012;50(9):1665-70. doi: 10.1515/cclm-2011-1854. Clin Chem Lab Med. 2012. PMID: 23100378

27

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.

Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S, Ando K, Nakamura N. Kojima M, et al. Leuk Lymphoma. 2013 Oct;54(10):2149-54. doi: 10.3109/10428194.2013.771398. Epub 2013 Mar 8. Leuk Lymphoma. 2013. PMID: 23363269

28

Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation.

Harkensee C, Oka A, Onizuka M, Middleton PG, Inoko H, Nakaoka H, Gennery AR, Ando K, Morishima Y; Japan Marrow Donor Programme (JMDP). Harkensee C, et al. Immunogenetics. 2013 Jun;65(6):417-27. doi: 10.1007/s00251-013-0691-z. Epub 2013 Mar 9. Immunogenetics. 2013. PMID: 23474535

29

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

Ogawa Y, Suzuki K, Sakai A, Iida S, Ogura M, Tobinai K, Matsumoto M, Matsue K, Terui Y, Ohashi K, Ishii M, Mukai HY, Ando K, Hotta T. Ogawa Y, et al. Cancer Sci. 2013 Jul;104(7):912-9. doi: 10.1111/cas.12172. Epub 2013 May 27. Cancer Sci. 2013. PMID: 23574271 Free PMC article. Clinical Trial.

30

High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription.

Kawada H, Kaneko M, Sawanobori M, Uno T, Matsuzawa H, Nakamura Y, Matsushita H, Ando K. Kawada H, et al. PLoS One. 2013 Apr 23;8(4):e62717. doi: 10.1371/journal.pone.0062717. Print 2013. PLoS One. 2013. PMID: 23626851 Free PMC article.

31

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M. Ohmachi K, et al. J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650408 Clinical Trial.

32

A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, Tobinai K, Lee JH, Kase M, Katsura K, Hotta T. Ogawa Y, et al. Int J Hematol. 2013 Aug;98(2):164-70. doi: 10.1007/s12185-013-1393-x. Epub 2013 Jul 12. Int J Hematol. 2013. PMID: 23846385 Clinical Trial.

33

Strong effect of mogamulizumab on splenic residual disease of adult T cell leukemia/lymphoma.

Ohgiya D, Machida S, Ichiki A, Amaki J, Aoyama Y, Kawai H, Miyamoto M, Murayama H, Onizuka M, Ando K. Ohgiya D, et al. Ann Hematol. 2014 Apr;93(4):719-20. doi: 10.1007/s00277-013-1874-2. Epub 2013 Aug 15. Ann Hematol. 2014. PMID: 23949316 No abstract available.

34

Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration.

Ibrahim AA, Yahata T, Onizuka M, Dan T, Van Ypersele De Strihou C, Miyata T, Ando K. Ibrahim AA, et al. Stem Cells. 2014 Apr;32(4):946-58. doi: 10.1002/stem.1577. Stem Cells. 2014. PMID: 24155177 Free article.

35

ACE deletion polymorphism is associated with a high risk of non-infectious pulmonary complications after stem cell transplantation.

Miyamoto M, Onizuka M, Machida S, Toyosaki M, Amaki J, Aoyama Y, Kawai H, Sato A, Hayama N, Ogawa Y, Kawada H, Ando K. Miyamoto M, et al. Int J Hematol. 2014 Feb;99(2):175-83. doi: 10.1007/s12185-013-1494-6. Epub 2013 Dec 21. Int J Hematol. 2014. PMID: 24363151

36

Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.

Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, Moriuchi M, Miyamoto M, Aoyama Y, Kawai H, Ichiki A, Hara R, Kawada H, Ogawa Y, Ando K. Sato A, et al. Cancer Sci. 2014 Sep;105(9):1170-5. doi: 10.1111/cas.12467. Epub 2014 Sep 8. Cancer Sci. 2014. PMID: 24974976 Free PMC article.

37

Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia.

Suzuki R, Matsushita H, Kawai H, Matsuzawa H, Tsuboi K, Watanabe S, Kawada H, Ogawa Y, Ando K. Suzuki R, et al. Leuk Res Rep. 2014 Jun 28;3(2):54-7. doi: 10.1016/j.lrr.2014.06.004. eCollection 2014. Leuk Res Rep. 2014. PMID: 25068103 Free PMC article.

38

Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia.

Kawai H, Matsushita H, Suzuki R, Sheng Y, Lu J, Matsuzawa H, Yahata T, Tsuma-Kaneko M, Tsukamoto H, Kawada H, Ogawa Y, Ando K. Kawai H, et al. Leuk Res. 2014 Dec;38(12):1451-9. doi: 10.1016/j.leukres.2014.08.015. Epub 2014 Aug 30. Leuk Res. 2014. PMID: 25217890

39

Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma.

Kawada H, Sawanobori M, Tsuma-Kaneko M, Wasada I, Miyamoto M, Murayama H, Toyosaki M, Onizuka M, Tsuboi K, Tazume K, Shirasugi Y, Ohmachi K, Ogawa Y, Kobayashi H, Ando K. Kawada H, et al. Tokai J Exp Clin Med. 2014 Sep 20;39(3):111-5. Tokai J Exp Clin Med. 2014. PMID: 25248425 Free article. Clinical Trial.

40

Migration of bone marrow-derived cells for endogenous repair in a new tail-looping disc degeneration model in the mouse: a pilot study.

Sakai D, Nishimura K, Tanaka M, Nakajima D, Grad S, Alini M, Kawada H, Ando K, Mochida J. Sakai D, et al. Spine J. 2015 Jun 1;15(6):1356-65. doi: 10.1016/j.spinee.2013.07.491. Epub 2014 Nov 24. Spine J. 2015. PMID: 25459743 Free article.

41

A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission.

Kojima M, Nakamura N, Yabe M, Tokunaka M, Kikuti YY, Kikuchi T, Murayama H, Moriuchi M, Tsuboi K, Ogawa Y, Ando K. Kojima M, et al. Int J Hematol. 2015 May;101(5):520-4. doi: 10.1007/s12185-014-1729-1. Epub 2015 Jan 3. Int J Hematol. 2015. PMID: 25555480

42

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M, Machida S, Kojima M, Shirasugi Y, Kawada H, Ogawa Y, Ando K. Amaki J, et al. Int J Hematol. 2015 Jun;101(6):543-53. doi: 10.1007/s12185-015-1766-4. Epub 2015 Mar 4. Int J Hematol. 2015. PMID: 25735499

43

Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.

Kojima M, Ogiya D, Kawai H, Miyamoto M, Ohmachi K, Ogawa Y, Nakamura N, Ando K. Kojima M, et al. Acta Haematol. 2015;134(3):181-2. doi: 10.1159/000371834. Epub 2015 May 27. Acta Haematol. 2015. PMID: 26022650 No abstract available.

44

Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies.

Kojima M, Ichinose A, Souri M, Osaki T, Kawai H, Amaki J, Numata H, Miyamoto M, Ogiya D, Tsuboi K, Ogawa Y, Ozawa S, Ando K. Kojima M, et al. Int J Hematol. 2016 Mar;103(3):341-7. doi: 10.1007/s12185-015-1917-7. Epub 2015 Nov 30. Int J Hematol. 2016. PMID: 26619833

45

A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.

Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, Ohmachi K, Uchida T, Hanson ME, Tanaka Y, Koh Y, Shimamoto T, Hotta T. Ogawa Y, et al. Int J Hematol. 2016 Jan;103(1):25-33. doi: 10.1007/s12185-015-1897-7. Epub 2015 Nov 30. Int J Hematol. 2016. PMID: 26619834 Clinical Trial.

46

Bacterial Pneumonia-induced Persistent Remission of Severe Immune Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation.

Onizuka M, Matsushita H, Machida S, Toyosaki M, Amaki J, Aoyama Y, Miyamoto M, Ando K. Onizuka M, et al. Intern Med. 2016;55(2):179-83. doi: 10.2169/internalmedicine.55.4724. Epub 2016 Jan 15. Intern Med. 2016. PMID: 26781020 Free article.

47

Four hepatosplenic T-cell lymphoma cases of Japanese patients.

Kawai H, Matsushita H, Ohmachi K, Kojima M, Machida S, Ogawa Y, Kawada H, Nakamura N, Ando K. Kawai H, et al. Leuk Res Rep. 2015 Dec 15;5:3-6. doi: 10.1016/j.lrr.2015.12.001. eCollection 2016. Leuk Res Rep. 2015. PMID: 26870659 Free PMC article.

48

Erratum to: Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies.

Kojima M, Ichinose A, Souri M, Osaki T, Kawai H, Amaki J, Numata H, Miyamoto M, Ogiya D, Tsuboi K, Ogawa Y, Ozawa S, Ando K. Kojima M, et al. Int J Hematol. 2016 May;103(5):602-3. doi: 10.1007/s12185-016-1988-0. Int J Hematol. 2016. PMID: 27084255 No abstract available.

49

Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report.

Kojima M, Ogiya D, Ichiki A, Hara R, Amaki J, Kawai H, Numata H, Sato A, Miyamoto M, Suzuki R, Machida S, Matsushita H, Ogawa Y, Kawada H, Ando K. Kojima M, et al. Leuk Res Rep. 2016 Jan 22;5:11-3. doi: 10.1016/j.lrr.2016.01.001. eCollection 2016. Leuk Res Rep. 2016. PMID: 27144119 Free PMC article.

50

Chédiak-Higashi-like granules and waxy Auer bodies in a case of acute promyelocytic leukemia.

Ogiya D, Matsushita H, Murayama H, Ando K. Ogiya D, et al. Int J Hematol. 2016 Dec;104(6):637-638. doi: 10.1007/s12185-016-2078-z. Epub 2016 Aug 18. Int J Hematol. 2016. PMID: 27539154 No abstract available.

51

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29. Int J Hematol. 2017. PMID: 27900638 Clinical Trial.

52

[Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].

Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T. Ogiya D, et al. Rinsho Ketsueki. 2016;57(11):2311-2318. doi: 10.11406/rinketsu.57.2311. Rinsho Ketsueki. 2016. PMID: 27941278 Clinical Trial. Japanese.

53

Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Onizuka M, Kojima M, Matsui K, Machida S, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Nakamura N, Ando K. Onizuka M, et al. Int J Hematol. 2017 Jul;106(1):141-145. doi: 10.1007/s12185-017-2181-9. Epub 2017 Jan 17. Int J Hematol. 2017. PMID: 28097534

54

A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.

Ogawa Y, Izutsu K, Kiguchi T, Choi I, Takatsuka Y, Ando K, Suzumiya J; Japanese Bendamustine CLL Study Group. Ogawa Y, et al. Int J Hematol. 2017 May;105(5):631-637. doi: 10.1007/s12185-016-2178-9. Epub 2017 Feb 3. Int J Hematol. 2017. PMID: 28160213 Clinical Trial.

55

The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period.

Kawai H, Matsushita H, Kawada H, Ogawa Y, Ando K. Kawai H, et al. Intern Med. 2017 Sep 1;56(17):2339-2342. doi: 10.2169/internalmedicine.8487-16. Epub 2017 Aug 10. Intern Med. 2017. PMID: 28794370 Free PMC article.

56

NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.

Hara R, Onizuka M, Matsusita E, Kikkawa E, Nakamura Y, Matsushita H, Ohgiya D, Murayama H, Machida S, Ohmachi K, Shirasugi Y, Ogawa Y, Kawada H, Ando K. Hara R, et al. Int J Hematol. 2017 Nov;106(5):666-674. doi: 10.1007/s12185-017-2294-1. Epub 2017 Aug 9. Int J Hematol. 2017. PMID: 28795321 Clinical Trial.

57

Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.

Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, Watanabe S, Sasao T, Obayashi Y, Onizuka M, Ohmachi K, Yoshiba F, Shirasugi Y, Ogawa Y, Kawada H, Nakamura N, Ando K. Ichiki A, et al. J Clin Exp Hematop. 2017;57(2):54-63. doi: 10.3960/jslrt.17029. J Clin Exp Hematop. 2017. PMID: 29021515 Free PMC article.

58

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.

Muguruma Y, Yahata T, Warita T, Hozumi K, Nakamura Y, Suzuki R, Ito M, Ando K. Muguruma Y, et al. Blood Cancer J. 2017 Dec 15;7(12):650. doi: 10.1038/s41408-017-0001-3. Blood Cancer J. 2017. PMID: 29242532 Free PMC article. No abstract available.

59

A case of diffuse large B-cell lymphoma with MYC gene cluster amplification related to chromothripsis.

Kojima M, Carreras J, Kikuti YY, Miyaoka M, Kikuchi T, Amaki J, Sato A, Ogiya D, Ando K, Nakamura N. Kojima M, et al. Leuk Lymphoma. 2018 Oct;59(10):2460-2464. doi: 10.1080/10428194.2017.1421753. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345169 No abstract available.

60

E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.

Ohmachi K, Ando K, Ogura M, Uchida T, Tobinai K, Maruyama D, Namiki M, Nakanishi T. Ohmachi K, et al. Cancer Sci. 2018 Mar;109(3):794-802. doi: 10.1111/cas.13513. Epub 2018 Feb 26. Cancer Sci. 2018. PMID: 29363235 Free PMC article. Clinical Trial.

61

Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.

Carreras J, Yukie Kikuti Y, Miyaoka M, Hiraiwa S, Tomita S, Ikoma H, Kondo Y, Shiraiwa S, Ando K, Sato S, Suzuki Y, Miura I, Roncador G, Nakamura N. Carreras J, et al. Am J Surg Pathol. 2018 Jul;42(7):936-950. doi: 10.1097/PAS.0000000000001071. Am J Surg Pathol. 2018. PMID: 29738359

62

Dysplastic features seen in a patient with acute myeloid leukemia harboring the KTM2A-TET1 fusion gene.

Kawai H, Matsushita H, Aoyama Y, Matsui K, Onizuka M, Ando K. Kawai H, et al. Int J Hematol. 2018 Jul;108(1):1-2. doi: 10.1007/s12185-018-2469-4. Epub 2018 May 9. Int J Hematol. 2018. PMID: 29744807 No abstract available.

63

Correction to: Dysplastic features seen in a patient with acute myeloid leukemia harboring the KMT2A-TET1 fusion gene.

Kawai H, Matsushita H, Aoyama Y, Matsui K, Onizuka M, Ando K. Kawai H, et al. Int J Hematol. 2018 Aug;108(2):232. doi: 10.1007/s12185-018-2476-5. Int J Hematol. 2018. PMID: 29948955

64

R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.

Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). Ogura M, et al. Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28. Cancer Sci. 2018. PMID: 29957865 Free PMC article. Clinical Trial.

65

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.

Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.

66

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.

Ohmachi K, Ando K, Kinoshita T, Kumagai K, Hatake K, Ishikawa T, Teshima T, Kato K, Izutsu K, Ueda E, Nakai K, Kuriki H, Tobinai K. Ohmachi K, et al. Jpn J Clin Oncol. 2018 Aug 1;48(8):736-742. doi: 10.1093/jjco/hyy087. Jpn J Clin Oncol. 2018. PMID: 30060000 Free PMC article. Clinical Trial.

67

Iron removal enhances vitamin C-induced apoptosis and growth inhibition of K-562 leukemic cells.

Tsuma-Kaneko M, Sawanobori M, Kawakami S, Uno T, Nakamura Y, Onizuka M, Ando K, Kawada H. Tsuma-Kaneko M, et al. Sci Rep. 2018 Nov 26;8(1):17377. doi: 10.1038/s41598-018-35730-8. Sci Rep. 2018. PMID: 30478296 Free PMC article.

68

A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22).

Suzuki R, Warita T, Nakamura Y, Kitamura Y, Aoyama Y, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Int J Hematol. 2019 Jun;109(6):731-736. doi: 10.1007/s12185-019-02603-3. Epub 2019 Jan 24. Int J Hematol. 2019. PMID: 30680670

69

Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.

Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Munakata W, et al. Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28. Cancer Sci. 2019. PMID: 30815927 Free PMC article. Clinical Trial.

70

A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma.

Ohmachi K, Ogura M, Suehiro Y, Ando K, Uchida T, Choi I, Ogawa Y, Kobayashi M, Fukino K, Yokoi Y, Okamura J. Ohmachi K, et al. Int J Hematol. 2019 Jun;109(6):657-664. doi: 10.1007/s12185-019-02635-9. Epub 2019 Mar 26. Int J Hematol. 2019. PMID: 30915717 Clinical Trial.

71

A Case of Composite Lymphoma with Extranodal NK/T-cell Lymphoma, Nasal-type and Diffuse Large B-cell Lymphoma.

Kawai H, Matsushita H, Kawakami S, Furuya D, Shiraiwa-Hara S, Ichiki A, Hara R, Aoyama Y, Ogiya D, Suzuki R, Machida S, Onizuka M, Shirasugi Y, Ogawa Y, Kawada H, Nakamura N, Ando K. Kawai H, et al. J Clin Exp Hematop. 2019;59(1):34-39. doi: 10.3960/jslrt.18038. J Clin Exp Hematop. 2019. PMID: 30918142 Free PMC article.

72

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein.

Kawai H, Matsushita H, Suzuki R, Kitamura Y, Ogawa Y, Kawada H, Ando K. Kawai H, et al. Neoplasia. 2019 Aug;21(8):788-801. doi: 10.1016/j.neo.2019.06.001. Epub 2019 Jul 3. Neoplasia. 2019. PMID: 31276931 Free PMC article.

73

Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.

Kawai H, Matsushita H, Akashi H, Furuya D, Kawakami S, Suzuki R, Moriuchi M, Ogawa Y, Kawada H, Nakamura N, Ando K. Kawai H, et al. Leuk Lymphoma. 2020 Apr;61(4):959-962. doi: 10.1080/10428194.2019.1691197. Epub 2019 Nov 27. Leuk Lymphoma. 2020. PMID: 31773997 Review. No abstract available.

74

Detection of 6pLOH in an aplastic anemia patient by in phase HLA genotyping.

Kikkawa E, Shiina T, Shigenari A, Ozaki Y, Suzuki S, Ando K, Onizuka M. Kikkawa E, et al. HLA. 2020 May;95(5):465-469. doi: 10.1111/tan.13807. Epub 2020 Feb 20. HLA. 2020. PMID: 31970935

75

Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.

Kojima M, Amaki J, Ogiya D, Ando K, Nakamura N. Kojima M, et al. J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13. J Clin Exp Hematop. 2020. PMID: 32404573 Free PMC article. Clinical Trial. No abstract available.

76

Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.

Suzuki R, Kawai H, Furuya D, Akashi H, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Tokai J Exp Clin Med. 2020 Jul 20;45(2):92-96. Tokai J Exp Clin Med. 2020. PMID: 32602108 Free article.

77

An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation.

Takahashi M, Toyosaki M, Matsui K, Machida S, Kikkawa E, Ota Y, Kaneko A, Ogawa Y, Ando K, Onizuka M. Takahashi M, et al. Int J Hematol. 2020 Nov;112(5):690-696. doi: 10.1007/s12185-020-02958-y. Epub 2020 Aug 8. Int J Hematol. 2020. PMID: 32770478

78

Overexpression of miR-669m inhibits erythroblast differentiation.

Kotaki R, Kawashima M, Yamaguchi A, Suzuki N, Koyama-Nasu R, Ogiya D, Okuyama K, Yamamoto Y, Takamatsu M, Kurosaki N, Ando K, Murata A, Ohtsuka M, Nakagawa S, Katagiri K, Kotani A. Kotaki R, et al. Sci Rep. 2020 Aug 11;10(1):13554. doi: 10.1038/s41598-020-70442-y. Sci Rep. 2020. PMID: 32782283 Free PMC article.

79

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, Adamia S, Ando K, Hideshima T, Anderson KC. Ogiya D, et al. Blood. 2020 Nov 12;136(20):2334-2345. doi: 10.1182/blood.2019004332. Blood. 2020. PMID: 32844992 Free PMC article.

80

Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions.

Shiraiwa S, Kikuti YY, Carreras J, Hara R, Aoyama Y, Ogiya D, Suzuki R, Toyosaki M, Ohmachi K, Ogawa Y, Kawada H, Sato S, Nakamura N, Ando K. Shiraiwa S, et al. J Clin Exp Hematop. 2020 Dec 15;60(4):159-168. doi: 10.3960/jslrt.20041. Epub 2020 Nov 4. J Clin Exp Hematop. 2020. PMID: 33148934 Free PMC article.

81

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma.

Suzuki R, Kitamura Y, Nakamura Y, Akashi H, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Oncotarget. 2020 Nov 3;11(44):3984-3997. doi: 10.18632/oncotarget.27775. eCollection 2020 Nov 3. Oncotarget. 2020. PMID: 33216827 Free PMC article.

82

A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.

Hara R, Kawada H, Kikuti YY, Kikkawa E, Harada K, Aoyama Y, Ogiya D, Toyosaki M, Suzuki R, Machida S, Ohmachi K, Onizuka M, Ogawa Y, Masuda R, Iwazaki M, Nakamura N, Ando K. Hara R, et al. Int J Hematol. 2021 Apr;113(4):606-610. doi: 10.1007/s12185-020-03046-x. Epub 2021 Jan 3. Int J Hematol. 2021. PMID: 33389657

83

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

Munakata W, Shirasugi Y, Tobinai K, Onizuka M, Makita S, Suzuki R, Maruyama D, Kawai H, Izutsu K, Nakanishi T, Shiba S, Hojo S, Ando K. Munakata W, et al. Cancer Sci. 2021 Mar;112(3):1123-1131. doi: 10.1111/cas.14822. Epub 2021 Feb 15. Cancer Sci. 2021. PMID: 33492746 Free PMC article. Clinical Trial.

84

Plasminogen activator inhibitor type-1 is a negative regulator of hematopoietic regeneration in the adipocyte-rich bone marrow microenvironment.

Harada K, Yahata T, Onizuka M, Ibrahim AA, Kikkawa E, Miyata T, Ando K. Harada K, et al. Biochem Biophys Res Commun. 2021 Jun 11;557:180-186. doi: 10.1016/j.bbrc.2021.04.017. Epub 2021 Apr 15. Biochem Biophys Res Commun. 2021. PMID: 33866038

85

A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.

Ohnishi K, Ohmachi K, Ando K, Yamamoto K, Ito T, Tanimoto M, Ohbayashi K, Ohyashiki K, Tsukasaki K, Naito K, Suzuki T, Ono T, Miyamura K, Kagami Y, Kinoshita T, Hotta T, Ogura M. Ohnishi K, et al. J Clin Exp Hematop. 2021 Sep 10;61(3):162-167. doi: 10.3960/jslrt.21004. Epub 2021 Jun 30. J Clin Exp Hematop. 2021. PMID: 34193755 Free PMC article. Clinical Trial.

86

Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Hara R, Onizuka M, Kikkawa E, Shiraiwa S, Harada K, Aoyama Y, Ogiya D, Toyosaki M, Suzuki R, Machida S, Ohmachi K, Ogawa Y, Kawada H, Matsushita H, Ando K. Hara R, et al. Ann Hematol. 2021 Oct;100(10):2479-2486. doi: 10.1007/s00277-021-04587-9. Epub 2021 Jul 11. Ann Hematol. 2021. PMID: 34247299

87

AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Miyaoka M, Kikuti YY, Carreras J, Itou A, Ikoma H, Tomita S, Shiraiwa S, Ando K, Nakamura N. Miyaoka M, et al. Pathol Int. 2022 Jan;72(1):35-42. doi: 10.1111/pin.13182. Epub 2021 Nov 2. Pathol Int. 2022. PMID: 34727403

88

Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Suzuki R, Kitamura Y, Ogiya D, Ogawa Y, Kawada H, Ando K. Suzuki R, et al. Int J Hematol. 2022 Feb;115(2):233-243. doi: 10.1007/s12185-021-03244-1. Epub 2021 Nov 5. Int J Hematol. 2022. PMID: 34741230

89

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease.

Hara R, Goto N, Furuya D, Kitahara T, Numata H, Watanabe S, Kawada H, Ando K. Hara R, et al. Case Rep Oncol. 2021 Nov 5;14(3):1574-1579. doi: 10.1159/000519568. eCollection 2021 Sep-Dec. Case Rep Oncol. 2021. PMID: 34949998 Free PMC article.

90

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells.

Kawakami S, Tsuma-Kaneko M, Sawanobori M, Uno T, Nakamura Y, Matsuzawa H, Suzuki R, Onizuka M, Yahata T, Naka K, Ando K, Kawada H. Kawakami S, et al. Sci Rep. 2022 Jan 13;12(1):704. doi: 10.1038/s41598-021-04654-1. Sci Rep. 2022. PMID: 35027628 Free PMC article.

91

Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.

Ikoma H, Miyaoka M, Hiraiwa S, Yukie Kikuti Y, Shiraiwa S, Hara R, Kojima M, Ohmachi K, Ando K, Carreras J, Nakamura N. Ikoma H, et al. Pathol Int. 2022 Jun;72(6):321-331. doi: 10.1111/pin.13223. Epub 2022 Mar 17. Pathol Int. 2022. PMID: 35297566

92

Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection.

Shiraiwa S, Harada K, Onizuka M, Kawakami S, Hara R, Aoyama Y, Amaki J, Ogiya D, Suzuki R, Toyosaki M, Machida S, Omachi K, Kawada H, Ogawa Y, Ando K. Shiraiwa S, et al. J Infect Chemother. 2022 Sep;28(9):1279-1285. doi: 10.1016/j.jiac.2022.05.014. Epub 2022 Jun 10. J Infect Chemother. 2022. PMID: 35691863

93

Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.

Ogiya D, Murayama N, Kamiya Y, Saito R, Shiraiwa S, Suzuki R, Machida S, Tazume K, Ando K, Yamazaki H. Ogiya D, et al. Ann Hematol. 2022 Sep;101(9):2013-2019. doi: 10.1007/s00277-022-04893-w. Epub 2022 Jun 22. Ann Hematol. 2022. PMID: 35732975

94

9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.

Shiraiwa S, Kikuti YY, Carreras J, Kondo Y, Ohmachi K, Ogawa Y, Kawada H, Sato S, Gion Y, Sato Y, Nakamura N, Ando K. Shiraiwa S, et al. Am J Surg Pathol. 2022 Aug 1;46(8):1017-1024. doi: 10.1097/PAS.0000000000001899. Epub 2022 Jul 18. Am J Surg Pathol. 2022. PMID: 35848760

95

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, Miyata T, Ando K, Harigae H. Takahashi N, et al. Cancer Med. 2023 Feb;12(4):4250-4258. doi: 10.1002/cam4.5292. Epub 2022 Sep 23. Cancer Med. 2023. PMID: 36151699 Free PMC article.

96

Mitochondrial Electron Transport Chain Complex II Dysfunction Causes Premature Aging of Hematopoietic Stem Cells.

Harada K, Yahata T, Onizuka M, Ishii T, Aziz Ibrahim A, Kikkawa E, Gondo Y, Ando K. Harada K, et al. Stem Cells. 2023 Jan 30;41(1):39-49. doi: 10.1093/stmcls/sxac072. Stem Cells. 2023. PMID: 36219686

97

Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome.

Hara R, Kitahara T, Numata H, Toyosaki M, Watanabe S, Kikkawa E, Ogawa Y, Kawada H, Ando K. Hara R, et al. Int J Hematol. 2023 May;117(5):684-693. doi: 10.1007/s12185-022-03523-5. Epub 2022 Dec 27. Int J Hematol. 2023. PMID: 36574168

98

Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.

Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, Aoi A, Hatsumichi M, Tobinai K. Munakata W, et al. Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28. Int J Hematol. 2023. PMID: 36576659 Free PMC article. Clinical Trial.

99

Aplastic Anemia with Epstein-Barr Virus Reactivation after Anti-thymocyte Globulin Therapy.

Kawarada Y, Hara R, Kitahara T, Numata H, Watanabe S, Yamada M, Ando K. Kawarada Y, et al. Intern Med. 2023 Sep 1;62(17):2553-2557. doi: 10.2169/internalmedicine.0539-22. Epub 2023 Feb 1. Intern Med. 2023. PMID: 36725050 Free PMC article.

100

Donor cord blood aging accelerates in recipients after transplantation.

Onizuka M, Imanishi T, Harada K, Aoyama Y, Amaki J, Toyosaki M, Machida S, Kikkawa E, Yamada S, Nakabayashi K, Hata K, Higashimoto K, Soejima H, Ando K. Onizuka M, et al. Sci Rep. 2023 Feb 14;13(1):2603. doi: 10.1038/s41598-023-29912-2. Sci Rep. 2023. PMID: 36788379 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,084 results

Search Page

Filters